scholarly journals MON-446 Anaplastic Thyroid Cancer Presenting with Brain Metastasis: 17-Year Progression Free Survival

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Kathryn Kay Howard ◽  
Morta Lapkus ◽  
Natalie Johnson ◽  
Sapna Nagar ◽  
Peter Czako

Abstract Background: Anaplastic Thyroid Cancer is the most aggressive thyroid cancer with a median survival of just five months. Long term survival has been reported in locally aggressive cases, but has yet to be reported in metastatic disease. Case Information: A 34-year-old male presented with symptoms of dizziness, confusion, intermittent headaches, and erratic behavior for two weeks. CT of the head revealed a 1 cm ring enhancing lesion in the left parietal lobe with surrounding vasogenic edema. He was taken to the operating room for a left parietal craniotomy and a vascular, solid mass was removed. Initial pathology suggested papillary thyroid origin due to positive staining for thyroid transcription factor (TTF) and thyroglobulin (Tg). On exam, he had a palpable 3 cm mass in the right thyroid lobe with no associated adenopathy. He underwent thyroidectomy to optimize post-operative radioactive iodine treatment. Intraoperative frozen section revealed anaplastic thyroid cancer and final pathology revealed anaplastic carcinoma identical to the brain lesion. The tumor pathology showed extension through the thyroid capsule with lymphovascular invasion and one of two positive lymph nodes. Post-operatively, he underwent 15 cycles of whole brain radiation therapy for a total of 35 Gy. Two additional brain lesions were identified after thyroidectomy and a third was identified after whole brain radiation. He underwent stereotactic radiosurgery of these three lesions less than two months after thyroidectomy. The patient went on to receive modified mantle field irradiation (46 cycles, total 55.2 Gy) to the neck, thyroid bed, and the upper mediastinum. Additionally, he received chemotherapy with doxorubicin 6-8 weeks and temozolomide for 2 years. Thyroid uptake studies showed minimal residual iodine-avid disease and, in the setting of chemotherapy-induced cytopenias, radioactive iodine treatment was not administered. The patient has currently survived 17 years post-treatment. His persistent, but stable, brain lesions are being followed with serial imaging. He remains clinically and neurologically asymptomatic. Conclusions: This is the first case presenting with long-term survival in a patient with metastatic anaplastic thyroid carcinoma. A multidisciplinary course with early aggressive surgical removal, adjuvant treatment with chemotherapy and radiation, and long term imaging follow up may be an acceptable treatment plan for stable patients. References: Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104-39.

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A882-A883
Author(s):  
Kathryn Kay Howard ◽  
Morta Lapkus ◽  
Natalie Luehmann ◽  
Sapna Nagar ◽  
Peter Czako

Abstract Anaplastic Thyroid Cancer is the most aggressive thyroid cancer with a median survival of just five months. Long term survival has been reported in locally aggressive cases but has yet to be reported in metastatic disease. This is a report of a 34-year-old male who presented with symptoms of dizziness, confusion, intermittent headaches, and erratic behavior for two weeks found to have metastatic anaplastic thyroid cancer. CT of the head revealed a 1 cm ring enhancing lesion and he was taken to the operating room for a left parietal craniotomy with mass removal. Initial pathology suggested papillary thyroid origin. His neck exam revealed a palpable 3 cm mass in the right thyroid lobe and he subsequently underwent total thyroidectomy. Final pathology revealed anaplastic carcinoma identical to the brain lesion. Post-operatively, he underwent 15 cycles of whole brain radiation therapy. Two additional brain lesions were identified after thyroidectomy and a third was identified after whole brain radiation. He underwent stereotactic radiosurgery of these three lesions less than two months after thyroidectomy. The patient went on to receive modified mantle field irradiation to the neck, thyroid bed, and the upper mediastinum and chemotherapy with doxorubicin for 6-8 weeks and temozolomide for 2 years. Radioactive iodine treatment was not administered. The patient has currently survived 17 years and his persistent, but stable, brain lesions are being followed with serial imaging. He remains clinically and neurologically asymptomatic. This is the first case presenting with long-term survival in a patient with metastatic anaplastic thyroid carcinoma.


2006 ◽  
Vol 69 (10) ◽  
pp. 489-491 ◽  
Author(s):  
Ai-Hung Liu ◽  
Li-Ying Juan ◽  
An-Hang Yang ◽  
Harn-Shen Chen ◽  
Hong-Da Lin

2020 ◽  
Vol 9 (9) ◽  
pp. 5430-5436
Author(s):  
Haejun Lee ◽  
Soo Young Kim ◽  
Seok-Mo Kim ◽  
Ho-Jin Chang ◽  
Yong Sang Lee ◽  
...  

2020 ◽  
pp. 15-21
Author(s):  
Tahseen Alrubai ◽  
Arwa Mohsun Khalil ◽  
Samaa AL Tabbah ◽  
Rasha Zaki

Introduction: Brain metastasis (BM) commonly occurs in patients with advanced lung cancer and is associated with poor prognosis and short survival periods. In some cases, select patients survive several years which is rare. Presentation of case: This case report highlights the long-term survival of a 55-year-old patient who was diagnosed with brain metastases from lung cancer three years ago and is currently alive following treatment with chemotherapy for the primary cancer and whole-brain radiation therapy and chemotherapy for the brain metastases. Since the diagnosis of brain metastases three years ago, the patient’s primary cancer has remained controlled and she is living a disease-free, functional life. Discussion: Literature review identified female gender, performance status, number of metastatic sites, the presence of a solitary lesion or single lesion, brain metastases later in their illness, adenocarcinoma histology, younger age, and patients with EGFR and ALK alterations, to be all as favorable prognostic factors associated with long term survival in patients with brain metastasis secondary to lung cancer. Conclusion: Further studies should be designed to investigate the factors that may relate to long term survival in patients with brain metastasis secondary to lung cancer. This should help further understand the treatment outcomes in these patients. Keywords: Brain Metastasis; Chemotherapy; Carboplatin; Gemcitabine; Whole-brain radiation; Non-small-cell lung cancer


Sign in / Sign up

Export Citation Format

Share Document